Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
401-420 of 2,251 trials

Colorectal Cancer: Post-Surgery Chemotherapy Study

We are investigating whether restarting chemotherapy after surgery helps patients with colorectal cancer that has spread to the liver live longer and stay cancer-free. This study compares different treatment approaches to find the best option.

Metastatic Colorectal Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesGastroenterologyOncology

Advanced Solid Tumors: GRWD5769 Treatment Study

We are testing the safety and effectiveness of GRWD5769 alone and with cemiplimab in patients with advanced solid tumors. This study aims to find out how well these treatments work and their tolerability.

Malignant Solid Tumor1-2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Sotatercept for Children with Pulmonary Artery Hypertension

We are studying the safety and effects of sotatercept in children aged 1 to under 18 with pulmonary artery hypertension. This research aims to improve treatment options for young patients already receiving standard care.

Pulmonary Arterial Hypertension3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteCardiologyPulmonology

Cutaneous Lupus Erythematosus: Litifilimab Injections

We are studying the long-term safety and effects of Litifilimab injections for adults with active cutaneous lupus erythematosus who have not responded to other treatments. This research aims to see if it can improve symptoms and overall quality of life.

Skin Lupus (Cutaneous Lupus Erythematosus)>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementDermatologyRheumatology

Bomedemstat vs Best Available Therapy for Essential Thrombocythemia

We are studying a new treatment for patients with essential thrombocythemia who haven't responded to hydroxyurea. The trial aims to see if bomedemstat is safer and more effective than current therapies.

Essential Thrombocythemia>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementHematology

Pediatric Cancer: Crizotinib Treatment Study

We are testing the safety and effectiveness of crizotinib, alone and with temsirolimus, for children with ALK, ROS1, or MET positive cancers. This study aims to find the best dose and understand how well these treatments work.

NeuroblastomaAnaplastic Large Cell LymphomaInflammatory Myofibroblastic Tumors6-12 monthsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesOncologyPediatrics

Chronic Kidney Disease: Finerenone Safety Study

We are studying the long-term safety of finerenone for children and young adults with chronic kidney disease. This trial looks at its effects when used alongside standard treatments like ACE inhibitors or ARBs.

Chronic Kidney DiseaseProteinuria1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNephrologyPediatrics

Dopaminergic Pathway Changes in Comatose Patients with Traumatic Brain Injury

We are studying how traumatic brain injuries affect dopamine pathways in patients who are in a coma. This research may help us understand recovery patterns and improve future treatments.

Traumatic Brain Injury>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboInvestigational MedicinesNeurologyOtolaryngology

Advanced Thyroid Cancer: Sacituzumab Govitecan Study

We are testing a new drug for patients with advanced differentiated and anaplastic thyroid neoplasms. The goal is to see if it can effectively control the disease and improve patient outcomes.

Thyroid Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesEndocrinologyOncology

Non-Transfusion-Dependent Thalassemia: Luspatercept Treatment

We are studying whether luspatercept can improve brain oxygen levels and blood flow in patients with non-transfusion-dependent thalassemia. The trial also looks at its effects on cognitive function and heart health.

Non-transfusion Dependent Beta-Thalassemia6-12 monthsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesHematologyNeurology

Cystic Fibrosis: Long-Term Study of BI 3720931 Gene Therapy

We are monitoring the health of individuals with cystic fibrosis who previously received the BI 3720931 gene therapy. This study aims to assess the long-term safety and effectiveness of the treatment.

Cystic Fibrosis>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesPulmonology

Prostate Cancer: 177Lu-PSMA Treatment Study

We are studying a new treatment for men with high-risk prostate cancer after initial therapies. The trial aims to see if this treatment helps prevent cancer from coming back and improves quality of life.

Prostate Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

High Cardiovascular Risk: Rosuvastatin vs. Combination Therapy

We are studying whether high-intensity rosuvastatin or a combination of rosuvastatin and ezetimibe can effectively lower cholesterol in patients at high or very high risk for heart disease. The goal is to see if these treatments help achieve specific cholesterol targets.

High Cholesterol≤3 monthsConfirmation phase (III)Monitoring phase (IV)≤5 visitsNo PlaceboInvestigational MedicinesCardiologyInternal Medicine

Dobutamine for Very Preterm Infants with Low Blood Flow

We are studying the lowest effective dose of dobutamine to help improve blood flow in very preterm infants. The trial also looks at how well the treatment works and its safety during the first few days after birth.

Neonates with Haemodynamic Insufficiency>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesCardiologyPediatrics

Prostate Cancer Recurrence: PSMA PET/CT vs. Salvage Radiotherapy

We are comparing a personalized treatment approach using PSMA PET/CT imaging with standard salvage radiotherapy for patients whose prostate cancer has returned after surgery. The goal is to see which method better helps manage their condition and improves quality of life.

Recurrent Prostate Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteOncology

Breast Cancer Treatment: Elacestrant with Olaparib

We are studying whether adding elacestrant to the standard treatment olaparib helps women with hormone receptor-positive, HER2-negative breast cancer and gBRCA1/2 mutations. This trial aims to improve progression-free survival and overall treatment outcomes.

Metastatic Breast Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Hematologic Malignancies: MK-1026 Treatment Study

We are evaluating a new treatment for patients with blood cancers to see if it is safe and effective in reducing symptoms. This study focuses on various types of hematologic malignancies, including CLL and MCL.

Blood CancerEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

Heart Failure: Stopping Medication After Cardiac Resynchronization Therapy

We are studying the effects of withdrawing medication in patients who have improved heart function after cardiac resynchronization therapy. This trial will help us understand the safety and changes in heart health when treatment is stopped.

Heart Failure>2 yearsMonitoring phase (IV)No PlaceboInvestigational MedicinesCardiologyInternal Medicine

HIV and Liver Health: Doravirine Study

We are exploring how the medication Doravirine affects liver fat and fibrosis in people living with HIV who have liver issues. This study aims to see if switching to Doravirine improves liver health over time.

Human Immunodeficiency Virus (HIV)1-2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesHepatologyInfectious DiseasesInternal Medicine

Triple-Negative Breast Cancer: MK-2870 with Pembrolizumab

We are studying a new treatment combining MK-2870 and pembrolizumab for people with triple-negative breast cancer who had surgery but did not respond completely. The trial aims to see if this combination works better than standard treatment options.

Triple Negative Breast Cancer>2 yearsConfirmation phase (III)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncology